List view / Grid view
25 January 2019 | By European Pharmaceutical Review
Researchers have suggested that benzodiazepines should be the first course of treatment for those with cardiovascular disease and anxiety...
23 January 2019 | By Iqra Farooq (European Pharmaceutical Review)
A study has found that long term aspirin use increases patients' risk of major bleeding events by 43 percent, with 1 in 200 having a major bleed...
7 December 2018 | By European Pharmaceutical Review
A study has shown that thousands of heart attacks and deaths caused by cardiovascular disease could be prevented through the use of statins...
22 October 2018 | By Iqra Farooq (European Pharmaceutical Review)
A 3D bioprinting technique could, in the future, allow the creation of human tissue structures for the analysis of various diseases...
1 October 2018 | By Iqra Farooq (European Pharmaceutical Review)
Portable biopharmaceutical drug manufacturers could be the future method of producing the drugs on demand for outbreaks of disease...
11 September 2018 | By Mike Stones
A new observational study has identified no benefit from prescribing statins to healthy pensioners aged over 75 to prevent heart disease...
8 August 2018 | By Mike Stones
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.
23 July 2018 | By European Pharmaceutical Review
A new online heart health calculator can predict the age of hearts and the risk to individuals of a serious cardiovascular event or death...
14 June 2018 | By European Pharmaceutical Review
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) demonstrate that canakinumab significantly reduced the rate of gout by more than half, compared to placebo, regardless of baseline serum urate level.
26 June 2017 | By University of Illinois College of Agricultural Consumer and Environmental Sciences (ACES)
Over the last decade, research has revealed more about the human gut microbiome—the environment within the gastrointestinal tract—where microbes, especially bacteria, reside.
10 January 2017 | By Niamh Marriott, Digital Editor
Novartis announced a collaboration and option agreement with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two novel treatments with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of lipoproteins known as Lp(a) and ApoCIII.
5 January 2017 | By Niamh Marriott, Digital Editor
In the trial, empagliflozin significantly reduced the relative risk of the combined primary endpoint of cardiovascular death, non-fatal heart attack by 14%...
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
28 June 2016 | By Victoria White, Digital Content Producer
A study has found that controversy over the risks and benefits of statins was followed by an increase in people stopping their statin treatment...
Follow: